Who
Jay S. Duker
President and CEO
Company insider
Files Form 4 as: President and CEO, EyePoint; Director, Sesen Bio.
In numbers
- Trades disclosed
- 121
- Buys
- 2
- Sells
- 0
- Bought
- $49K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 20 Jan 2015
- Last trade
- 10 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jul 2026filed 14 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —16,667 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code F | $119K8,059 at $14.72 | filing |
| 10 Jul 2026filed 14 Jul 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,667 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,667 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —16,667 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code F | $119K8,059 at $14.72 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code J | $1.0M76,766 at $13.11 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code J | $1.0M76,766 at $13.11 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code J | $459K52,500 at $8.75 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code J | $459K52,500 at $8.75 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code J | $459K52,500 at $8.75 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code J | $933K97,500 at $9.57 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code J | $933K97,500 at $9.57 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code J | $459K52,500 at $8.75 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code J | $933K97,500 at $9.57 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code J | $933K97,500 at $9.57 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code J | $1.0M76,766 at $13.11 | filing |
| 23 Mar 2026filed 24 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code J | $1.0M76,766 at $13.11 | filing |
| 16 Mar 2026filed 16 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $20K1,500 at $13.15 | filing |
| 16 Mar 2026filed 16 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $20K1,500 at $13.15 | filing |
News
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Jefferies Financial Group to "Hold"EYPT · tickerreport.com · 19 Oct 2026Critical Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK)EYPT · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Jay S. Duker; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.